SCHEMBL2664779

SCHEMBL2664779

Cc1nc(NC(=O)c2cc(OCc3ccccc3F)cc(OC(C)C)c2)sc1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 9/20 0.63
RARA P10276 1/20 0.51
RARB P10826 1/20 0.51
RARG P13631 1/20 0.51
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
PKM P14618 2/20 0.48
CSNK2A2 P19784 1/20 0.46
CSNK2A1 P68400 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
GRM4 Q14833 1/20 0.42
KAT6A Q92794 3/20 0.42
NOX1 Q9Y5S8 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664784 0.86 GCK (0.66) GCKRARARARBRARGNPC1
SCHEMBL2664682 0.86 GCK (0.64) GCKRARARARBRARGNPC1
SCHEMBL2664778 0.85 GCK (0.63) GCKRARARARBRARGNPC1
SCHEMBL2664750 0.83 GCK (0.65) GCKRARARARBRARGNPC1
SCHEMBL2664751 0.83 GCK (0.69) GCKRARARARBRARGCSNK2A2
SCHEMBL2664680 0.83 GCK (0.64) GCKRARARARBRARGRAB9A
SCHEMBL2664916 0.82 GCK (0.74) GCKRARARARBRARGNPC1
SCHEMBL2664749 0.82 GCK (0.66) GCKRARARARBRARGNPC1
SCHEMBL2664790 0.81 GCK (0.59) GCKRARARARBRARGNPC1
SCHEMBL12021539 0.81 GCK (0.49) GCKRARARARBRARGNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 GCK 2/4885RARA 3925/4885RARB 3902/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 GCK 2/4885RARA 3925/4885RARB 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.